文献速递肿瘤 PET/CT核素与放射性配体治疗

神经内分泌肿瘤中心常规使用[64Cu]Cu-DOTATATE PET/CT:2249次连续扫描的转诊模式与图像结果

Routine Use of [64Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.
PubMed 文献 · J Nucl Med · 2024-11-01

本研究系统分析了哥本哈根大学医院Rigshospitalet在2018年4月10日至2022年5月2日期间全部临床常规[64Cu]Cu-DOTATATE PET/CT扫描的转诊指征与图像结果,共纳入1290例患者的2249次扫描。最常见指征为无临床进展证据的神经内分泌肿瘤监测(703次,31.3%),该场景下超过三分之一的扫描检出疾病进展,且大部分进展仅PET可见。作者据此认为该场景可能可被归类为「适当」。

要点

  • 无临床进展证据的神经内分泌肿瘤监测是最常见指征(703次,31.3%),现行适当使用标准(AUC)将其定义为「可能适当」。
  • 该监测场景中疾病进展检出超过三分之一(461/2249次扫描中进展占20.5%,监测场景占703次中的超过三分之一),且大部分进展仅PET可见(99/461次,21.5%)。
  • 作者认为该监测场景可能可被归类为「适当」。

核心结论

  • 本研究提供的真实世界数据可能有助于支持制定包括适当使用标准(AUC)在内的64Cu-DOTATATE/生长抑素受体(SSTR)PET/CT指南。
  • 现行AUC中列为「可能适当」的部分场景在本数据中频繁出现。
  • 无临床进展证据的神经内分泌肿瘤监测是最常见的64Cu-DOTATATE PET/CT指征,其中超过三分之一检出疾病进展,且大部分进展仅PET可见;作者因此认为该场景可能可被归类为「适当」。

研究设计与样本

  • 研究纳入2018年4月10日(临床启用之日)至2022年5月2日期间在哥本哈根大学医院Rigshospitalet执行的全部临床常规64Cu-DOTATATE PET/CT扫描。
  • 研究审阅每次扫描的转诊文本与图像报告,并按AUC所列临床场景对指征进行分类。
  • 共纳入1290例患者的2249次64Cu-DOTATATE PET/CT扫描。

主要发现

  • 无临床进展证据、经传统影像与SSTR PET均可见的神经内分泌肿瘤患者监测为最常见指征(AUC定义为「可能适当」),共703次扫描(31.3%)。
  • 神经内分泌肿瘤诊断后初始分期(AUC「适当」)为221次扫描(9.8%),治愈性意向手术后再分期(AUC「可能适当」)为241次扫描(10.7%)。
  • 筛选适合肽受体放射性核素治疗的患者(AUC「适当」)为95次扫描(4.2%),肽受体放射性核素治疗完成后再分期(AUC「适当」)为115次扫描(5.1%)。
  • AUC未定义指征的扫描为371次(16.5%)。
  • 图像结果分析显示:669次扫描(29.7%)无疾病,582次(25.9%)疾病稳定,461次(20.5%)疾病进展;461次进展扫描中有99次(21.5%)进展在PET上检出而CT未检出。

关键数值与推荐

  • AUC将无临床进展证据的神经内分泌肿瘤监测定义为「可能适当」,本研究中该指征占703次扫描(31.3%)。
  • AUC将神经内分泌肿瘤诊断后初始分期定义为「适当」,本研究中该指征占221次扫描(9.8%)。
  • AUC将治愈性意向手术后再分期定义为「可能适当」,本研究中该指征占241次扫描(10.7%)。
  • AUC将筛选适合肽受体放射性核素治疗的患者定义为「适当」,本研究中该指征占95次扫描(4.2%)。
  • AUC将肽受体放射性核素治疗完成后再分期定义为「适当」,本研究中该指征占115次扫描(5.1%)。

临床怎么用

  • 作者认为,无临床进展证据的神经内分泌肿瘤监测这一场景可能可被归类为「适当」。
  • 原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of somatostatin receptor (SSTR) PET/CT, using 68Ga-based tracers or [64Cu]Cu-DOTATATE (64Cu-DOTATATE), in the management of patients with neuroendocrine neoplasm (NEN) is guided by appropriate use criteria (AUC). In this study, we performed systematic analyses of referral patterns and image findings of routine 64Cu-DOTATATE PET/CT scans to support AUC development. Methods: We included all clinical routine 64Cu-DOTATATE PET/CT scans performed between April 10, 2018 (start of clinical use), and May 2, 2022, at Copenhagen University Hospital-Rigshospitalet. We reviewed the referral text and image report of each scan and classified the indication according to clinical scenarios as listed in the AUC. Results: In total, 1,290 patients underwent 2,249 64Cu-DOTATATE PET/CT scans. Monitoring of patients with NEN seen both on conventional imaging and on SSTR PET without clinical evidence of progression was the most common indication (defined as "may be appropriate" in the AUC) and accounted for 703 (31.3%) scans. Initial staging after NEN diagnosis ("appropriate" in the AUC) and restaging after curative-intent surgery ("may be appropriate" in the AUC) accounted for 221 (9.8%) and 241 (10.7%) scans, respectively. Selection of patients eligible for peptide receptor radionuclide therapy ("appropriate" in the AUC) and restaging after peptide receptor radionuclide therapy completion ("appropriate" in the AUC) accounted for 95 (4.2%) and 115 (5.1%) scans, respectively. The number of scans performed for indications not defined in the AUC was 371 (16.5%). Image result analysis revealed no disease in 669 scans (29.7%), stable disease in 582 (25.9%), and progression in 461 (20.5%). In 99 of the 461 (21.5%) scans, progression was detected on PET but not on CT. Conclusion: Our study provided real-life data that may contribute to support development of 64Cu-DOTATATE/SSTR PET/CT guidelines including AUC. Some scenarios listed as "may be appropriate" in the current AUC were frequent in our data. Monitoring of patients with NEN without clinical evidence of progression was the most frequent indication for 64Cu-DOTATATE PET/CT, in which disease progression was detected in more than one third, and a large proportion was visible by PET only. We therefore conclude that this scenario could potentially be classified as appropriate.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Carlsen EA, Loft M, Johnbeck CB, et al. Routine Use of [64Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans. J Nucl Med. 2024. PMID: 39362765. doi:10.2967/jnumed.124.267939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。